Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Actavis Inc    

ACTAVIS INC
Mes dernières consult.
Most popular
Report
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 15 892 M
EBIT 2017 7 624 M
Net income 2017 -3 984 M
Debt 2017 24 537 M
Yield 2017 1,55%
Sales 2018 16 277 M
EBIT 2018 7 790 M
Net income 2018 1 190 M
Debt 2018 22 310 M
Yield 2018 1,59%
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 5,50x
EV / Sales2018 5,24x
Capitalization 62 943 M
More Financials
Company
Allergan Plc engages in the research, development, and manufacture of pharmaceutical products.It operates through the following segments: US Specialized Therapeutics; US General Medicine, and International.The US Specialized Therapeutics segment includes sales and expenses relating to branded... 
Sector
Pharmaceuticals
Calendar
11/01Earnings Release
More about the company
Surperformance© ratings of Actavis Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ACTAVIS INC
02:12p ALLERGAN : to Present Latest Studies of Ulipristal Acetate for Uterine Fibroids ..
10:55a ALLERGAN : Issues Investor FAQ on Federal District Court RESTASIS Patent Decisio..
10/19 ALLERGAN : Academy of Managed Care Pharmacy AMCP Foundation and Allergan Offered..
10/19 ALLERGAN : Announces that the FDA Accepts New Drug Application for Ulipristal Ac..
10/19 ALLERGAN : Announces Settlement on RESTASIS® Cyclosporine Ophthalmic Emulsion 0...
10/19 ALLERGAN : to Present Data From More Than 20 Abstracts at the 2017 Fall Clinical..
10/19 SYNDAX PHARMACEUTICALS : Expands Pipeline with Exclusive Worldwide License to Al..
10/19 ALLERGAN : Issues Investor FAQ on Federal District Court RESTASIS® Patent Decisi..
10/18 ALLERGAN : ruling casts doubt on tribal patent strategy
10/18 ALLERGAN : to Present New Data at the World Congress of Gastroenterology at ACG ..
More news
Sector news : Pharmaceuticals - NEC
03:13pDJEuropean Corporate Roundup for Monday
02:26pDJDrug Makers Find 'Branded Generics' Are a Source for Growth
01:53p ASTRAZENECA : among backers as Swiss cancer biotech raises $200 million
11:08a European shares flat as banks weigh, Spain lags again
11:03aDJEuropean Corporate Roundup for Monday
More sector news : Pharmaceuticals - NEC
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 241 $
Spread / Average Target 28%
EPS Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Robert A. Stewart Chief Operating Officer
Maria Teresa Hilado Chief Financial Officer
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
Sector and Competitors
1st jan.Capitalization (M$)
ACTAVIS INC62 943
JOHNSON & JOHNSON23.60%382 202
NOVARTIS13.97%226 404
PFIZER12.13%216 886
ROCHE HOLDING LTD.0.77%207 116
MERCK AND COMPANY8.51%174 223